1
|
Noordhuis MG, Kop EA, van der Vegt B, Langendijk JA, van der Laan BFAM, Schuuring E, de Bock GH. Biological tumor markers associated with local control after primary radiotherapy in laryngeal cancer: A systematic review. Clin Otolaryngol 2020; 45:486-494. [PMID: 32246586 PMCID: PMC7318351 DOI: 10.1111/coa.13540] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 02/11/2020] [Accepted: 03/22/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND The choice of treatment in laryngeal cancer is mainly based on tumor stage, post-treatment morbidity and quality of life. Biological tumor markers might also be of potential clinical relevance. OBJECTIVE OF THE REVIEW The aim was to systematically review the value of published biological tumor markers to predict local control in laryngeal cancer patients treated with definitive radiotherapy. TYPE OF REVIEW Systematic review. SEARCH STRATEGY PubMed, Embase, Cochrane Library. EVALUATION METHOD A literature search was performed using multiple terms for laryngeal cancer, radiotherapy, biological markers, detection methods and local control or survival. Studies regarding the relation between biological tumor markers and local control or survival in laryngeal cancer patients primarily treated with radiotherapy were included. Markers were clustered on biological function. Quality of all studies was assessed. Study selection, data extraction and quality assessment was performed by two independent reviewers. RESULTS A total of 52 studies out of 618 manuscripts, concerning 118 markers, were included. EGFR and P53 showed consistent evidence for not being predictive of local control after primary radiotherapy, whereas proliferation markers (ie high Ki-67 expression) showed some, but no consistent, evidence for being predictive of better local control. Other clusters of markers (markers involved in angiogenesis and hypoxia, apoptosis markers, cell cycle, COX-2 and DNA characteristics) showed no consistent evidence towards being predictors of local control after primary radiotherapy. CONCLUSIONS Cell proliferation could be of potential interest for predicting local control after primary radiotherapy in laryngeal cancer patients, whereas EGFR and p53 are not predictive in contrast to some previous analyses. Large diversity in research methods is found between studies, which results in contradictory outcomes. Future studies need to be more standardised and well described according to the REMARK criteria in order to have better insight into which biomarkers can be used as predictors of local control after primary radiotherapy.
Collapse
Affiliation(s)
- Maartje G. Noordhuis
- Dept. of Otorhinolaryngology/Head and Neck SurgeryUniversity Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
| | - Emiel A. Kop
- Dept. of Otorhinolaryngology/Head and Neck SurgeryUniversity Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
| | - Bert van der Vegt
- Dept. of Pathology and Medical BiologyUniversity Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
| | - Johannes A. Langendijk
- Dept. of Radiation OncologyUniversity of GroningenUniversity Medical Center GroningenGroningenThe Netherlands
| | - Bernard F. A. M. van der Laan
- Dept. of Otorhinolaryngology/Head and Neck SurgeryUniversity Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
| | - Ed Schuuring
- Dept. of Pathology and Medical BiologyUniversity Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
| | - Geertruida H. de Bock
- Dept. of Epidemiology and StatisticsUniversity Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
| |
Collapse
|
2
|
Corvò R, Antognoni P, Sanguineti G. Biological Predictors of Response to Radiotherapy in Head and Neck Cancer: Recent Advances and Emerging Perspectives. TUMORI JOURNAL 2018; 87:355-63. [PMID: 11989586 DOI: 10.1177/030089160108700601] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The study of new biological parameters has received considerable attention in radiotherapy during the last decade due to their potential value in predicting treatment response in squamous cell carcinoma of the head and neck (SCC-HN) and the foreseen possibility of selecting altered fractionation radiotherapy for the individual patient. Although there are established clinical parameters in SCC-HN patients that relate to radiation response (extent of disease, hemoglobin level), recent advances with direct measurement of tumor oxygenation, inherent radiosensitivity and proliferation rate have increased the promise of individualization of treatment strategy according to these radiobiologically based parameters. Molecular research has now identified a host of new biological parameters with potential predictive utility; oncogenes, tumor suppressor genes, cell-cycle control genes, apoptosis genes and angiogenesis genes have been extensively studied and correlated with radiation response. Moreover, study of the epidermal growth factor receptor signal-transduction system as a possible response modulator has recently fostered molecular strategies which employ blockade of the receptor to down-regulate tumor growth. This article briefly reviews and analyzes the main controversial issues and drawbacks that hinder the general use of biological parameters for predicting tumor response to radiotherapy. It highlights the future perspectives of radiotherapy predictive assay research and the need to shift from single-parameter analysis to multiparametric studies which take into account several potential predictors that together are involved in different biological and clinical pathways.
Collapse
Affiliation(s)
- R Corvò
- UO Oncologia Radioterapica, Istituto Nazionale per la Ricerca sul Cancro, Genoa.
| | | | | |
Collapse
|
3
|
|
4
|
Sapci T, Filizel F, Karavus A, Akbulut UG, Karavus M. Lead article: The prognostic significance of proliferating cell nuclear antigen (pcna) in laryngeal cancer. Indian J Otolaryngol Head Neck Surg 2012; 50:354-61. [PMID: 23119458 DOI: 10.1007/bf03000687] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Squamous cell carcinoma arising from upper aerodigestive tract carries with it a significant morbidity and mortality and, over the last few decades, its incidence has steadily increased. The management of patients requires thorough investigation to determine the local, regional, and distant extent of the disease, and treatment options include surgery, radiotherapy, chemotherapy, or combinations of these.Despite the large number of therapeutic and hsitopathologic studies in print, there is currently no morphologic or cytologic feature available which consistenly predicts outcome in patients with laryngeal carcinoma. The use of proliferating cell nuclear antigen (PCNA), a newly available marker of a cell's proliferative activity ( S-phase fraction), was evaluated in 25 cases of squamous cell carcinoma of the larynx. PCNA scores differed, statistically significantly as far as the localization of the lesion, pathological grade, clinical stage, presence of lymph node metastases and prognosis of the patients were concerned.These data suggest that PCNA is an indicator of the malignant potential of the larynx. PCNA can be used in decision making for treatment and assessing prognosis in carcinoma of the larynx.
Collapse
Affiliation(s)
- T Sapci
- Department of Otorhinolaryngology Head and Neck Surgery, PTT Education spital, ISTANBUL
| | | | | | | | | |
Collapse
|
5
|
Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 2004; 15:1319-29. [PMID: 15319236 DOI: 10.1093/annonc/mdh299] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Cell proliferative activity has been extensively investigated in head and neck tumors. Ki67/MIB-1 immunostaining, tritiated thymidine or bromodeoxyuridine labeling indices, DNA S-phase fraction, proliferating cell nuclear antigen expression, potential doubling time and analysis of the nucleolar organizer region associated proteins (AgNORs) have shown significant correlation with prognosis in 4806 cases of tumors of the oral cavity, salivary glands, pharynx and larynx. However, this was not observed in 2968 other reported cases. Discrepancies may depend on various factors: the heterogeneity of the series, which include tumors from various anatomic sites and patients treated with different therapy, and the lack of standardization of methods for assessing cell proliferation. Furthermore, none of the methods currently applied can by themselves define the actual proliferative activity, as it depends both on the proportion of cells committed to the cycle (growth fraction) and the speed of the cell cycle. Indeed, the actual proliferative activity of a tumor could well be measured by the equation [PA = Ki67 or MIB-1 scores x AgNORs], as we did in pharyngeal carcinoma. Provided that large and homogeneous series are evaluated by standardized methods, cell proliferative activity can still be regarded as an inexpensive and reliable prognostic factor in head and neck tumors.
Collapse
Affiliation(s)
- A Pich
- Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin, Italy.
| | | | | |
Collapse
|
6
|
León X, Quer M, Orús C, de Vega M, Vergés J, Gañán L. [Treatment of T1N0 glottis carcinoma with radiotherapy. Results at our center and review of the literature]. ACTA OTORRINOLARINGOLOGICA ESPANOLA 2003; 54:39-47. [PMID: 12733319 DOI: 10.1016/s0001-6519(03)78382-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE To evaluate the results of radiotherapy in the treatment of patients with T1N0 glottic squamous cell carcinoma. MATERIAL AND METHODS Retrospective study of a cohort of 338 patients with T1N0 glottic carcinoma treated with radiotherapy at our institution between 1985-1997. A review of the literature published during the last ten years was carried out. RESULTS Local control with radiotherapy in our patients was 82%, reaching 97% when salvage surgery was included. The local control with radiotherapy in most of the published series ranges between 81.90%. CONCLUSIONS Treatment with radiotherapy achieves local control in early glottic carcinomas (T1N0) in 80-90% of cases. In our centre such treatment achieved local control in 82% of cases.
Collapse
Affiliation(s)
- X León
- Servicio de Otorrinolaringología, Hospital de la Santa Creu i Sant Pau, Avda, San Antoni Ma, Claret, 167, 08025 Barcelona
| | | | | | | | | | | |
Collapse
|
7
|
Blánquez MJ, Regadera J, Mariño J, Newman RE, Notario V. Gradual deregulation and loss of PCPH expression in the progression of human laryngeal neoplasia. Mol Carcinog 2002; 35:186-95. [PMID: 12489110 DOI: 10.1002/mc.10091] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
PCPH is a gene involved in the regulation of eukaryotic cell proliferation and stress response. Recently, analyses of human and animal solid tumors and cell lines suggested that PCPH protein deregulation may participate in neoplastic progression. To test this possibility, we first examined PCPH expression in several laryngeal carcinoma cell lines by Western analysis. The results showed the presence of altered PCPH polypeptides in these cells, accompanied by the loss of the PCPH form present in normal laryngeal epithelial cells, a deregulated expression pattern similar to that reported previously. We then analyzed PCPH expression in 59 dysplastic lesions of the human larynx, representative of the mild, moderate, and severe stages of the disease. Immunohistochemical data showed that, compared with normal laryngeal mucosa, PCPH expression in the dysplastic samples was associated with areas of epithelial cell maturation rather than with regions of increased proliferation. Furthermore, PCPH expression decreased parallel to the increase in cellular atypia of the dysplastic samples: PCPH either was expressed at very low levels or not expressed in cases of severe dysplasia/carcinoma in situ. This trend toward loss of PCPH expression along malignant progression of the larynx was confirmed by the low to null expression of PCPH in samples of invasive laryngeal carcinoma and by the complete absence of PCPH immunostaining in a laryngeal carcinoma-derived liver metastasis. These results indicated that PCPH protein analysis might allow for the distinction between grades of laryngeal dysplasia. In addition, detection of altered PCPH polypeptides by Western analysis potentially can be applied to the early identification of laryngeal squamous cell carcinoma.
Collapse
Affiliation(s)
- María José Blánquez
- Department of Anatomy, Veterinary School, Universidad Complutense, Madrid, Spain
| | | | | | | | | |
Collapse
|
8
|
Esposito JP, Camargo RS, Longatto Filho A, Di Loreto C, Kanamura CT, Tolosa EMCD. Expressão imuno-histoquímica dos marcadores pcna, KI67 e p53 em carcinomas epidermóides do trato aerodigestivo superior. Rev Col Bras Cir 2000. [DOI: 10.1590/s0100-69912000000500008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
OBJETIVO: Os carcinomas epidermóides do trato aerodigestivo superior são tumores de comportamento biológico heterogêneo. O objetivo deste trabalho é verificar se a expressão imuno-histoquímica dos marcadores Ki67, PCNA e P53 apresenta correlações com parâmetros prognósticos clínico-patológicos. MÉTODOS: Determinação da expressão imuno-histoquímica dos antígenos Ki67, PCNA e P53 em espécimes tumorais fixados e embebidos em parafina de 53 pacientes com carcinoma epidermóide em diferentes sítios primários do trato aerodigestivo superior. RESULTADOS: Os marcadores tiveram altos índices de expressão imuno-histoquímica, sendo 46,5% para o Ki67, 66,5% para o PCNA e 36,5% para o P53. Não houve correlação da expressão do Ki67 e do PCNA com o estadiamento TNM (AJCC), nem com o grau de malignidade. A expressão do Ki67 apresentou correlação positiva com a expressão do PCNA (p = 0,037). O mesmo aconteceu para o PCNA e o número de mitoses por campo (p = 0,001). CONCLUSÕES: De acordo com estes resultados, concluiu-se que a determinação da imunorreatividade dos marcadores Ki67 e PCNA é um método objetivo e quantificável para avaliar proliferação celular que pode subsidiar as informações prognósticas.
Collapse
|
9
|
Raybaud H, Fortin A, Bairati I, Morency R, Monteil RA, Têtu B. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma. Int J Oral Maxillofac Surg 2000. [DOI: 10.1016/s0901-5027(00)80122-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Donoff RB, Todd R, Elovic A, Gallagher GT, Chou MY, Wong DT. Prediction of human oral cancer radiation responsiveness by histone (H3) mRNA in situ hybridization: a preliminary report. J Oral Maxillofac Surg 1998; 56:1410-6. [PMID: 9846539 DOI: 10.1016/s0278-2391(98)90406-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
PURPOSE Cell cycle kinetics are believed to be a key determinant in radiation responsiveness. However, histomorphologic analysis remains an unreliable method of identifying proliferating cells. In this study, the fraction of cells undergoing division within oral cancer biopsy samples was used to predict the responsiveness of the tumor to radiation therapy. PATIENTS AND METHODS Eighteen cases of T1 or T2 squamous cell carcinoma of the floor of the mouth with known clinical outcomes were identified. All were treated at the Massachusetts General Hospital with external beam radiation therapy alone. The fraction of proliferating cells was determined using in situ hybridization of histone (H3) mRNA expression. Tissue viability and mRNA status was verified using in situ hybridization for beta-actin mRNA expression. RESULTS Matching the fraction of oral tumor cells positively labeled for histone (H3) mRNA (histone labeling index or HLI) with the actual clinical outcome showed that the HLI of radioresponsive oral tumors (12 cases) was 0.336+/-0.185 (approximately 34%+/-19%), whereas that for radioresistant oral tumors (six cases) was 0.088+/-0.078 (approximately 9%+/-7.8%). Using t-test statistical analysis for unpaired samples showed that the difference in HLI between the two groups was significantly different (P=.0068). CONCLUSIONS It is concluded that the use of in situ detection of histone (H3) mRNA may be a useful adjunctive criterion in the choice of treatment for human oral cancer.
Collapse
Affiliation(s)
- R B Donoff
- Department of Oral and Maxillofacial Surgery, Harvard School of Dental Medicine, Massachusetts General Hospital, Boston, USA
| | | | | | | | | | | |
Collapse
|
11
|
Grabenbauer GG, Steininger H, Meyer M, Fietkau R, Brunner T, Heinkelmann P, Hornung J, Iro H, Spitzer W, Kirchner T, Sauer R, Distel L. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol 1998; 47:175-83. [PMID: 9683366 DOI: 10.1016/s0167-8140(98)00016-4] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE To determine whether the immunohistochemical expression of proliferation-associated antigens (proliferating cell nuclear antigen, MIB1) and the nuclear p53 reactivity in addition to total tumor volume, nodal CT density and T and N category are predictive for overall survival and locoregional tumor control in patients with squamous cell carcinoma of the head and neck region. MATERIALS AND METHODS Between October 1989 and September 1993, 87 patients with biopsy proven head and neck cancer were randomly allocated to receive radiation alone or simultaneous radiation and chemotherapy as part of a multicenter trial with a total of 298 randomized patients. There were only inoperable lesions in UICC (1992) stage III (8%) and IV (92%). Radiotherapy was delivered with 180 cGy twice daily up to a total dose of 7020 cGy in 51 days. Three cycles of 2340 cGy each were separated by a rest period of 11 days. Chemotherapy consisted of cis-DDP, 5-fluorouracil and leucovorin and was repeated on days 22 and 44. Routinely-processed paraffin-embedded sections were stained using monoclonal antibodies for detection of proliferation-associated antigens (MIB1 and PCNA) and p53 oncoprotein to determine the labeling index (LI). In addition, the total tumor volume and the percentage of necrosis were measured using CT data. The median follow-up was 3.9 years (range 1.9-5.0 years). RESULTS The overall survival and locoregional control for all 87 patients were 34 and 39% at 3 years, respectively. The addition of chemotherapy resulted in a better overall survival (27 versus 47%, P = 0.03) but did not influence locoregional control (31 versus 47%, P = 0.08). In univariate analysis, nodal CT density (P < 0.0001), total tumor volume (P < 0.0001), age (P = 0.001) and the MIB1-LI (P = 0.04) had a significant impact on overall survival. However, in the final Cox model only the nodal CT density (P = 0.0003) and age (P = 0.05) were independent prognostic factors for survival and only the nodal CT density (P = 0.0006) was an independent prognostic factor for locoregional control. The expression of the p53 oncoprotein was not found to have a clear predictive value. CONCLUSION Nodal CT density, total tumor volume and age will remain the relevant prognostic factors in stage III/IV head and neck cancer.
Collapse
Affiliation(s)
- G G Grabenbauer
- Department of Radiation Therapy, University Hospitals of Erlangen, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Grabenbauer GG, Matzel KE, Schneider IH, Meyer M, Wittekind C, Matsche B, Hohenberger W, Sauer R. Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? Dis Colon Rectum 1998; 41:441-50. [PMID: 9559628 DOI: 10.1007/bf02235757] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE This study contained herein assessed long-term results, toxicity, and prognostic variables following combined modality therapy of patients with International Union Against (Cancer Classification T1-4, N0-3, M0 squamous-cell carcinoma of the anal canal. PATIENTS AND METHODS Between 1985 and 1996, 62 patients completed treatment with combined modality therapy. A median total dose of 50 Gy was given to the primary, perirectal, presacral, and inguinal nodes followed by a local boost in selected cases. 5-Fluorouracil was scheduled as a continuous infusion of 1,000 mg/m2 per 24 hours on days 1 to 5 and 29 to 33 and mitomycin C as a bolus of 10 mg/m2 on days 1 and 29. Routinely processed paraffin-embedded sections were stained using monoclonal antibodies for detection of proliferating cell nuclear antigen and MIB1 (Ki-67) antigen to determine the labeling index. In addition, DNA ploidy was assessed after Feulgen staining. RESULTS Actuarial cancer-related survival, no evidence of disease survival, and colostomy-free survival rates at five years were 81, 76, and 86 percent, respectively. In univariate analysis, T category (T1/2 vs. T3/4) was predictive for no evidence of disease survival (87 vs. 59 percent; P = 0.03) and colostomy-free survival (94 vs. 73 percent; P = 0.05). N category (N0 vs. N1-3) influenced actuarial cancer-related survival (85 vs. 58 percent; P = 0.002) and no evidence of disease survival (80 vs. 53 percent; P = 0.02). A higher proliferative potential as measured by the MIB1 labeling index was associated with a better colostomy-free survival (90 vs. 50 percent; P = 0.04). In multivariate analysis, actuarial cancer-related survival was only influenced by the N category (P = 0.03) and no evidence of disease survival by N category (P = 0.03) and mitomycin C dose (P = 0.04). Salvage abdominoperineal resection achieved long-term control in only four of seven patients with local failures. CONCLUSION Treatment with a combination of radiotherapy and chemotherapy is safe and effective for patients with anal canal carcinoma. Abdominoperineal resection is indicated as a salvage procedure in nonresponding and recurrent lesions and may be of benefit in a small subgroup of patients with poor prognostic factors.
Collapse
Affiliation(s)
- G G Grabenbauer
- Department of Radiation Oncology, University Hospitals of Erlangen-Nürnberg, Erlangen, Germany
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Xie X, Clausen OPF, Sudbö J, Boysen M. Diagnostic and prognostic value of nucleolar organizer regions in normal epithelium, dysplasia, and squamous cell carcinoma of the oral cavity. Cancer 1997. [DOI: 10.1002/(sici)1097-0142(19970601)79:11<2200::aid-cncr19>3.0.co;2-#] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Xin Xie
- Department of Otolaryngology, National Hospital, Oslo, Norway
| | | | - Jon Sudbö
- Department of Pathology, The Norwegian Radiumhospital, University of Oslo, Oslo, Norway
| | - Morten Boysen
- Department of Otolaryngology, National Hospital, Oslo, Norway
| |
Collapse
|
14
|
Cappellai JO. Histopathology And Pathologic Prognostic Indicators Of Laryngeal Cancer. Otolaryngol Clin North Am 1997. [DOI: 10.1016/s0030-6665(20)30244-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
15
|
Namyslowski G, Klimala J, Kokocinska D, Misiolek M. Squamous cell carcinoma antigen levels in patients with different stages of laryngeal cancer. Eur Arch Otorhinolaryngol 1997; 254 Suppl 1:S154-6. [PMID: 9065653 DOI: 10.1007/bf02439749] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
An attempt was undertaken to evaluate the usefulness of squamous cell carcinoma antigen (SCC Ag) in different stages of squamous cell carcinoma of the larynx. Antigen levels were determined in blood serum before treatment in 25 patients with laryngeal cancer treated at the II ENT Department, Silesian Medical School in Zabrze. Ages were 39-65 years (mean, 56.6 years). Fifteen healthy volunteers of similar ages served as controls. SCC Ag was estimated by an enzyme-immunological method using the Abbot set. Increasing levels of SCC Ag were found in 14 patients (65%). The mean SCC Ag level before treatment in the tumor group was 2.93 +/- 0.23 ng/ml and 0.79 +/- 0.19 ng/ml in the control group (standard, 1.5 ng/ml). Mean SCC Ag levels depending on the clinical stage of disease were: stage I, 1.52 ng/ml; stage II, 2.16 ng/ml; stage III, 3.03 ng/ml; stage IV, 4.57 ng/ml. Differences in all groups were statistically significant when compared to the healthy controls (P < 0.05).
Collapse
Affiliation(s)
- G Namyslowski
- II ENT Department, Silesian Medical School, Zabrze, Poland
| | | | | | | |
Collapse
|
16
|
Munck-Wikland E, Edström S, Jungmark E, Kuylenstierna R, Lindholm J, Auer G. Nuclear DNA content, proliferating-cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions. Int J Cancer 1994; 56:95-9. [PMID: 7903288 DOI: 10.1002/ijc.2910560117] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Squamous epithelial cancer in situ (CIS) of the upper aerodigastric tract is a histopathologically well-defined condition. However, in clinical practice, morphological grading of dysplasia is difficult and shows large variability. The biology of CIS remains enigmatic, and there is yet no reliable way to predict whether a CIS lesion will progress to invasive cancer, remain stable or regress. In the search for markers able to foretell clinical outcome, we performed image DNA cytometry (ICM) and immunohistochemical staining for PCNA as well as p53 in 38 laryngeal CIS lesions, of which 9 progressed to invasive cancer. The majority of the CIS lesions displayed high-grade DNA aberration, a high PCNA-positive rate, and every third lesion was p53-positive by immunostaining. The lesions which progressed to invasive cancer showed a clear tendency towards more pronounced DNA aberration, a higher percentage of intense PCNA staining and more frequent p53 positivity. By combining the results from the analyses of DNA, PCNA and p53 in a prognostic index for each individual case, we correctly classified 82% of the lesions as progressors or non-progressors.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antigens, Neoplasm/analysis
- Antigens, Neoplasm/metabolism
- Biomarkers, Tumor/analysis
- Biomarkers, Tumor/metabolism
- Carcinoma in Situ/chemistry
- Carcinoma in Situ/epidemiology
- Carcinoma in Situ/metabolism
- Carcinoma, Squamous Cell/chemistry
- Carcinoma, Squamous Cell/epidemiology
- Carcinoma, Squamous Cell/metabolism
- Cell Nucleus/chemistry
- Cell Nucleus/metabolism
- DNA, Neoplasm/analysis
- DNA, Neoplasm/metabolism
- Discriminant Analysis
- Female
- Humans
- Immunohistochemistry
- Laryngeal Neoplasms/chemistry
- Laryngeal Neoplasms/epidemiology
- Laryngeal Neoplasms/metabolism
- Male
- Middle Aged
- Nuclear Proteins/analysis
- Nuclear Proteins/metabolism
- Prognosis
- Proliferating Cell Nuclear Antigen
- Tumor Suppressor Protein p53/analysis
- Tumor Suppressor Protein p53/metabolism
Collapse
Affiliation(s)
- E Munck-Wikland
- Department of Oto-rhino-laryngology, Karolinska Hospital, Stockholm, Sweden
| | | | | | | | | | | |
Collapse
|